MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

MC

520.2

+5.24%↑

SANES

8.168

+1.38%↑

SAF

284.7

-1.49%↓

BBVA

15.465

-0.55%↓

BNP

76.49

+0.18%↑

Search

Sartorius Stedim Biotech.

Open

SectorFinance

176.4 1.61

Overview

Share price change

24h

Current

Min

173.35

Max

176.45

Key metrics

By Trading Economics

Income

-23M

93M

Sales

400K

745M

P/E

Sector Avg

75.693

27.333

EPS

1.18

Dividend yield

0.39

Profit margin

12.43

Employees

10,030

EBITDA

-55M

201M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+26.36% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.39%

3.62%

Next Earnings

16 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-2.8B

17B

Previous open

174.79

Previous close

176.4

News Sentiment

By Acuity

31%

69%

143 / 534 Finance

Technical Score

By Trading Central

Confidence

Bullish Evidence

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

27 Aug 2025, 22:51 UTC

Earnings

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H Rev $4.01B

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H Adj EPS $1.84

27 Aug 2025, 23:57 UTC

Earnings

Trip.com Group 1H EPS $1.82

27 Aug 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 Aug 2025, 23:39 UTC

Earnings

Correction to Nvidia Earnings Article -- WSJ

27 Aug 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 Aug 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 Aug 2025, 22:58 UTC

Earnings

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 Aug 2025, 22:57 UTC

Earnings

South32 FY Free Cash Flow $192 Million

27 Aug 2025, 22:56 UTC

Earnings

South32 FY Total Capital Expenditure $1.35 Billion

27 Aug 2025, 22:56 UTC

Earnings

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 Aug 2025, 22:55 UTC

Earnings

South32 Net Cash $123 Million at June 30

27 Aug 2025, 22:54 UTC

Earnings

South32: Focused on Maintaining Strong Operating Momentum

27 Aug 2025, 22:53 UTC

Earnings

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 Aug 2025, 22:53 UTC

Earnings

South32 Extends Capital Management Program for 12 Months

27 Aug 2025, 22:52 UTC

Earnings

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 Aug 2025, 22:51 UTC

Earnings

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 Aug 2025, 22:51 UTC

Earnings

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 Aug 2025, 22:50 UTC

Earnings

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 Aug 2025, 22:50 UTC

Earnings

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 Aug 2025, 22:45 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 Aug 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 Aug 2025, 22:44 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 Aug 2025, 22:43 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 Aug 2025, 22:43 UTC

Earnings

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 Aug 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 Aug 2025, 22:42 UTC

Earnings

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 Aug 2025, 22:40 UTC

Earnings

Sandfire Resources Net Debt $123 Million at June 30

27 Aug 2025, 22:40 UTC

Earnings

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

26.36% upside

12 Months Forecast

Average 221.44 EUR  26.36%

High 240 EUR

Low 174 EUR

Based on 9 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

202.7 / 211.7Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

143 / 534 Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.